Buscador avanzado
Ver artículo
Av. Diabetol. 2010;26(2):79-89

Disminuir tamaño de letra Aumentar tamaño de letra Imprimir texto

Metformin: a pharmacological approach integrating hyperinsulinemia and breast cancer at the molecular, cellular and clinical levels

Revisión - Vol.26 N.2  Marzo-abril 2010
B. Martín-Castillo1, A. Vázquez-Martín2, C. Oliveras-Ferraros3, J. A. Menéndez4

 Filiaciones de autores


The possibility exists to adopt insulin reduction for preventive and therapeutic purposes in breast cancer. In this regard, recent interest has been focused on the insulin sensitizer metformin, a biguanide derivative that significantly re- duces breast cancer incidence and improves breast cancer patient’s survival in type 2 diabetics. The ability of metformin to activate AMP-activated protein kinase (AMPK), a key regulator of energy balance in the single cell and the whole organism, largely explains metformin’s anti-breast cancer activity. Here, we review the multifaceted and redundant mechanisms through which met- formin-reprogrammed energy metabolism at both the organismal and the cel- lular level may constitute a novel and valuable strategy to prevent and treat breast cancer disease.the malignant phenotype were largely considered a consequence


Correspondencia: Javier A. Menéndez, Ph.D. Catalan Institute of Oncology. Girona (ICO-Girona). Dr. Josep
Trueta University Hospital. Ctra. França, s/n. E-17007 Girona, Catalonia (Spain).

Palabras clave

diabetes metformina cáncer de mama adult stem cells AMP-activada proteína kinasa AMP-cinasa

‹ Volver